RECEIVED CENTRAL FAX CENTER NOV 1 8 2004

Serial No. 09/828,870 File 10 April 2001 Page 2

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LASERJET 3200

Listing of Claims:

Claims 1-39 (Canceled)

Claim 40 (New): A method of identifying an agent capable of modulating GD domain mediated heterodimerization, comprising

carrying out a heterodimerization assay which includes a first polypeptide and a second polypeptide, wherein the first polypeptide is SEQ ID NO: 36 and the second polypeptide is Bcl-x_L, and an agent;

determining whether said agent inhibits or augments heterodimerization of said first polypeptide to said second polypeptide;

wherein if inhibition or augmentation of heterodimerization is determined, it indicates that said agent is capable of modulating GD domain mediated heterodimerization.

Claim 41 (New): The method of claim 40, wherein Bcl-x_L is labeled.

Claim 42 (New): The method of claim 40, wherein Bcl-x_L is present in a fusion protein.

Claim 43 (New): The method of claim 42, wherein said fusion protein is GST-Bcl-x_L.

Claim 44 (New): The method of claim 40, wherein said agent inhibits heterodimerization of SEQ ID NO: 36 with Bcl-xL.

Clam 45 (New): The method of claim 40, wherein said agent augments heterodimerization of SEQ ID NO: 36 with Bcl-x_L.

BEST AVAILABLE COPY

Serial No. 09/828,870 File 10 April 2001 Page 3

Claim 46 (New): A method of identifying a GD domain-mediated heterodimerization modulator comprising incubating a test compound with a polypeptide having SEQ ID NO: 36 and Bcl-xL, and assaying for inhibition or activation of binding between SEQ ID NO: 36 and Bcl-x_L.

Claim 47 (New): The method of claim 46, wherein said Bcl-x₁ is labeled.

HP LASERJET 3200

Claim 48 (New): The method of claim 46, wherein said Bcl-x_L is present in a fusion protein.

Claim 49(New): The method of claim 48, wherein said fusion protein is GST-Bcl-x₁.

Claim 50 (New): The method of claim 46, wherein said agent inhibits heterodimerization of SEQ ID NO: 36 and Bcl-x_L.

Clam 51 (New): The method of claim 46, wherein said agent augments heterodimerization of SEQ ID NO: 36 and Bcl-x_L.

Claim 52 (New): A method of identifying an agent capable of modulating apoptosis in a cell, said method comprising

assaying an ability of the agent to modulate a heterodimerization activity between a GD domain of a protein or a polypeptide and a Bcl-x_L protein or a polypeptide, wherein the heterodimerization activity is defined by an ability of the GD domain to interact with the Bcl-x_L protein or a polypeptide, and

measuring an increase or decrease in the heterodimerization activity, thereby identifying said agent capable of modulating apoptosis in the cell.

Claim 53 (New): The method of claim 52, wherein the GD domain is characterized in SEQ ID NO:36.

23

p.5

Serial No. 09/828,870 File 10 April 2001 Page 4

Claim 57 (New): The method of claim 52, wherein the increase in heterodimerization activity represents an increase in apoptosis.

Claim 58 (New): The method of claim 52, wherein the decrease in heterodimerization activity represents a decrease in apoptosis.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items	checked:
☐ BLACK BORDERS	
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES	
☐ FADED TEXT OR DRAWING	
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING	
☐ SKEWED/SLANTED IMAGES	
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS	
GRAY SCALE DOCUMENTS	·
☐ LINES OR MARKS ON ORIGINAL DOCUMENT	
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUAL	JTY
OTHER:	

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.